All Comments by Michael G. Agadjanyan

  1. Dale Schenk, 59, Pioneer of Alzheimer’s Immunotherapy
  2. Bapineuzumab Phase 3: Target Engagement, But No Benefit
  3. Smuggling Antibodies to BACE Across the Blood-Brain Barrier
  4. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.
  5. DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.
  6. Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice.
  7. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy.
  8. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
  9. A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta.
  10. Immunotherapy Update: Toward Patches and Creams
  11. Aβ Star is Born? Memory Loss in APP Mice Blamed on Oligomer
  12. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety.
  13. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.
  14. Immunotherapy Protects against Synaptic Effects of Soluble Amyloid-β Oligomers
  15. Pilot Study Shows Promise of Passive Immunotherapy